Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Merck
AstraZeneca
Moodys
McKinsey

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Claims for Patent: 8,288,349

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,288,349
Title:Anti-angiogenic compounds
Abstract: The present invention provides AA targeting compounds which comprise AA targeting agent-linker conjugates which are linked to a combining site of an antibody. Various uses of the compounds are provided, including methods to treat disorders connected to abnormal angiogenesis.
Inventor(s): Bradshaw; Curt William (San Diego, CA), Bhat; Abhijit Suresh (Encinitas, CA), Lai; Jing-Yu (San Diego, CA), Doppalapudi; Venkata R. (San Diego, CA), Liu; Dingguo (San Diego, CA)
Assignee: Covx Technology Ireland, Ltd. (Ranalagh Village, Dublin, IE)
Application Number:11/938,766
Patent Claims:1. An anti-angiogenic (AA) targeting agent comprising a peptide comprising the following sequence: TABLE-US-00037 (SEQ ID NO: 43) R.sup.1-Q.sup.1 (AcK).sup.2 Y.sup.3 Q.sup.4 P.sup.5 L.sup.6 D.sup.7 E.sup.8 (AcK).sup.9 D.sup.10 K.sup.11 T.sup.12 L.sup.13 Y.sup.14 D.sup.15 Q.sup.16 F.sup.17 M.sup.18 L.sup.19 Q.sup.20 Q.sup.21 G.sup.22-R.sup.2

wherein R.sup.1 is CH.sub.3, C(O)CH.sub.3, C(O)CH.sub.3, C(O)CH.sub.2CH.sub.3, C(O)CH .sub.2CH.sub.3, C(O)CH(CH.sub.3)CH.sub.3, C(O)CH.sub.2CH.sub.2CH.sub.2CH.sub.3, C(O)CH(CH.sub.3)CH.sub.2CH.sub.3,C(O)C.sub.6H.sub.5, C(O)CH.sub.2CH.sub.2(CH.sub.2CH.sub.2O).sub.1-5Me, dichlorobenzoyl (DCB), difluorobenzoyl (DFB), pyridinyl carboxylate (PyC) or amido-2-PEG, an amino protecting group, a lipid fatty acid group or a carbohydrate; and R.sup.2 is OH, NH.sub.2, NH(CH.sub.3), NHCH.sub.2CH.sub.3, NHCH.sub.2CH.sub.2CH.sub.3, NHCH(CH.sub.3)CH.sub.3, NHCH.sub.2CH.sub.2CH.sub.2CH.sub.3, NHCH(CH.sub.3)CH.sub.2CH.sub.3, NHC.sub.6H.sub.5, NHCH.sub.2CH.sub.2OCH.sub.3, NHOCH.sub.3, NHOCH.sub.2CH.sub.3, a carboxy protecting group, a lipid fatty acid group or a carbohydrate, and pharmaceutically acceptable salts, stereoisomers, and solvates thereof.

2. An AA targeting agent or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein R.sup.1 is C(O)CH.sup.3.

3. An AA targeting agent or pharmaceutically acceptable salt thereof as claimed in claim 1, wherein R.sup.2 is NH.sub.2.

4. A compound or pharmaceutically acceptable salt thereof having the formula: Linker --[AA targeting agent] or Linker' -[AA targeting agent] wherein: [AA targeting agent] is the AA targeting agent as claimed in claim 1, and Linker is a linear or branched linker moiety having a formula --X-(recognition group Y)--Z--, and Linker' is a linear or branched linker moiety having the formula X-(recognition group Y)-Z', and wherein: X is attached to the AA targeting agent via the side chain of K.sup.11, and is a biologically compatible connecting chain including any atom selected from the group consisting of C, H, N, O, P, S, F, CL, Br, and I, and may comprise a polymer or block co-polymer, (recognition group Y) is an optionally present recognition group comprising at least a ring structure; and Z is a reactive group that is capable of forming a covalent bond with an amino acid side chain in a combining site of an antibody and Z' is an attachment moiety comprising a covalent link to an amino acid side in a combining site of an antibody.

5. The compound or pharmaceutically acceptable salt thereof as claimed in claim 4, wherein the (recognition group Y) has the optionally substituted structure: ##STR00283## wherein a, b, c, d, and e are independently carbon or nitrogen; f is carbon, nitrogen, oxygen, or sulfur; (recognition group Y) is attached to X and Z independently at any two ring positions of sufficient valence; and no more than four of a, b, c, d, e, or f are simultaneously nitrogen.

6. The compound or pharmaceutically acceptable salt thereof as claimed in claim 5, wherein a, b, c, d, and e are each carbon.

7. The compound or pharmaceutically acceptable salt thereof as claimed in claim 6, wherein (recognition group Y) is phenyl.

8. The compound or pharmaceutically acceptable salt thereof as claimed in claim 4, wherein Z if present is selected from the group consisting of substituted 1,3-diketones or acyl beta-lactams.

9. The compound or pharmaceutically acceptable salt thereof as claimed in claim 4, wherein Z if present has the structure: ##STR00284## and wherein Z', if present, has the structure: ##STR00285## wherein q=0-5 and Antibody-N--if present is a covalent bond to a side chain in a combining site of an antibody.

10. The compound or pharmaceutically acceptable salt thereof as claimed in claim 9, wherein q=2.

11. The compound or pharmaceutically acceptable salt thereof as claimed in claim 4, wherein X is attached to side chain of K.sup.11, is substituted or unsubstituted and is selected from R.sup.22[CH.sub.2--CH.sub.2--O].sub.tR.sup.23, R.sup.22cycloalkylR.sup.23, R.sup.22arylR.sup.23, or R.sup.22heterocyclylR.sup.23 , wherein: R.sup.22 and R.sup.23 are independently a covalent bond, --O--, --S--, NR.sup.b--, substituted or unsubstituted straight or branched chain C.sub.2-50 alkylene substituted or unsubstituted straight or branched chain C.sub.2-50 heteroalkylene substituted or unsubstituted straight or branched chain C.sub.2-50 alkenylene, or substituted or unsubstituted C.sub.2-50 heteroalkenylene; R.sup.b, at each occurrence is independently hydrogen , substituted or unsubstituted C.sub.1-10 alkyl, substituted or unsubstituted C.sub.3-7 cycloalkyl-C.sub.1-6alkyl, or substituted or unsubstituted aryl C.sup.1-6 alkyl; t=2-50; and the size of R.sup.22 and R.sup.23 are such that the backbone length of X remains 200 atoms or less.

12. The compound or pharmaceutically acceptable salt thereof as claimed in claim 4, wherein X is: ##STR00286## wherein v and w are each independently 1, 2, 3, 4, or 5 and are selected such that the backbone length of X is 6-12 atoms, and R.sup.b is hydrogen, substituted or unsubstituted C.sub.1-10 alkyl, substituted or unsubstituted C.sub.3-7 cycloalkyl--C.sub.1-6alkyl, or substituted or unsubstituted aryl C.sup.1-6 alkyl.

13. The compound or pharmaceutically acceptable salt thereof as claimed in claim 12, wherein X--Y is: ##STR00287## Wherein v=1 or 2; w=1 or 2 and R.sup.b is hydrogen.

14. The compound or pharmaceutically acceptable salt thereof as claimed in claim 4, comprising the structure: ##STR00288##

15. The compound or pharmaceutically acceptable salt thereof as claimed claim 4, comprising the structure: ##STR00289##

16. The compound or pharmaceutically acceptable salt thereof as claimed in claim 15, wherein the antibody is a catalytic antibody.

17. The compound or pharmaceutically acceptable salt thereof as claimed in claim 16, wherein the antibody is an aldolase catalytic antibody.

18. The compound or pharmaceutically acceptable salt thereof as claimed in claim 17, wherein the antibody is a full length antibody, Fab, Fab', F(ab')2, Fv, dsFv, scFv, V.sub.H, diabody, or minibody comprising V.sub.H and V.sub.L domains from h38c2, or is an antibody comprising the V.sub.H and V.sub.L domains from h38c2 and a constant domain selected from the group consisting of IgG1, IgG2, IgG3, and IgG4, or is h38c2 IgG1.

19. The compound or pharmaceutically acceptable salt thereof as claimed in claim 15, wherein the Antibody comprises SEQ ID NO:189 and SEQ ID NO:190.

20. A pharmaceutical composition comprising a therapeutically effective amount of an AA targeting agent or pharmaceutically acceptable salt thereof of claim 1.

21. The pharmaceutical compound or pharmaceutically acceptable salt thereof as claimed in claim 20, further comprising a therapeutically effective amount of one or more chemotherapeutic agent.

22. The pharmaceutical compound or pharmaceutically acceptable salt thereof as claimed in claim 21, wherein the chemotherapeutic agent is selected from the group consisting of Aldesleukin, Alemtuzumab, Alitretinoin, Allopurinol, Altretamine, Anastrozole, Arsenic trioxide, Asparaginase, Bevacizumab, Bexarotene capsules, Bexarotene gel, Bleomycin, Busulfan intravenous, Busulfan oral, Calusterone, Capecitabine, Carboplatin, Carmustine, Celecoxib, Cetuximab, Chlorambucil, Cinacalchet, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, actinomycin D, Danileukin diftitox, Darbepoetin alfa, Daunorubicin, Dexrazoxane, Docetaxel, Doxorubicin, Dromostanolone Propionate, Elliott's B Solution, Epoetin alfa/beta, Erlotinib, Estramustine, Etoposide phosphate, Etoposide, Exemestane, Filgrastim, Floxuridine, Fludarabine, Fluorouracil, Fulvestrant, Gemcitabine, Gemtuzumab ozogamicin, Goserelin acetate, Hydroxyurea, Ibritumomab tiuxetan, Idarubicin, Ifosfamide, Imatinib mesylate, Interferon alfa-2a, Irinotecan, Letrozole, Leucovorin, Levamisole, Lomustine, Meclorethamine, nitrogen mustard, Megestrol acetate, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methoxsalen, Mitomycin, Mitotane, Mitoxantrone, Nandrolone phenpropionate, Nelarabine, Nofetumomab, Oprelvekin, Oxaliplatin, Paclitaxel, Palonosetron, Pamidronate, Pegademase, Pegaspargase, Pegfilgrastim, Pemetrexed, Pentostatin, Pipobroman, Plicamycin, mithramycin, Porfimer sodium, Procarbazine, Rasburicase, Rituximab, Sargramostim, Streptozocin, Talc, Tamoxifen, Temozolomide, Teniposide, Testolactone, Thioguanine, Thiotepa, Topotecan, Toremifene, Tositumomab, Trastuzumab, Tretinoin, Uracil Mustard, Valrubicin, Vinblastine, Vincristine, Vinorelbine, Zoledronate, Sorafenib, Sutent, Thalomid, Revlimid, Vatalanib, ZD-6474, Neovastat, GSK-786024, AEE-788, AG-13736, AMG706, AZD-2171, BIBF-1120, CP-547,632, Midostaurin, SU-6668, CDP-791, PI-88, PCK-3145, Atiprimod, A6, Angiostatin, Cilengitide, Enodstatin, rPF4, Vitakin, Volociximab, 2-methoxyestradiol, AP-23573, Cancertinib, Actimid, Combretastatin A4 prodrug, Endo Tag 1, Enzastaurin, Ceflatonin, Silipide, INGN-241, OSI-461, Patupilone, Squalamine, Tacedinaline, UCN-01, UK-356202, Prednisolone, Methyl-prednisolone, Dexamethasone, and Epirubicin.

23. A pharmaceutical composition or pharmaceutically acceptable salt thereof comprising a therapeutically effective amount of the compound as claimed in claim 19.

24. The pharmaceutical compound or pharmaceutically acceptable salt thereof as claimed in claim 23, further comprising a therapeutically effective amount of one or more chemotherapeutic agent.

25. The pharmaceutical compound or pharmaceutically acceptable salt thereof as claimed in claim 24, wherein the chemotherapeutic agent is selected from the group consisting of Aldesleukin, Alemtuzumab, Alitretinoin, Allopurinol, Altretamine, Anastrozole, Arsenic trioxide, Asparaginase, Bevacizumab, Bexarotene capsules, Bexarotene gel, Bleomycin, Busulfan intravenous, Busulfan oral, Calusterone, Capecitabine, Carboplatin, Carmustine, Celecoxib, Cetuximab, Chlorambucil, Cinacalchet, Cisplatin, Cladribine, Clofarabine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, actinomycin D, Danileukin diftitox, Darbepoetin alfa, Daunorubicin, Dexrazoxane, Docetaxel, Doxorubicin, Dromostanolone Propionate, Elliott's B Solution, Epoetin alfa/beta, Erlotinib, Estramustine, Etoposide phosphate, Etoposide, Exemestane, Filgrastim, Floxuridine, Fludarabine, Fluorouracil, Fulvestrant, Gemcitabine, Gemtuzumab ozogamicin, Goserelin acetate, Hydroxyurea, Ibritumomab tiuxetan, Idarubicin, Ifosfamide, Imatinib mesylate, Interferon alfa-2a, Irinotecan, Letrozole, Leucovorin, Levamisole, Lomustine, Meclorethamine, nitrogen mustard, Megestrol acetate, Melphalan, Mercaptopurine, Mesna, Methotrexate, Methoxsalen, Mitomycin, Mitotane, Mitoxantrone, Nandrolone phenpropionate, Nelarabine, Nofetumomab, Oprelvekin, Oxaliplatin, Paclitaxel, Palonosetron, Pamidronate, Pegademase, Pegaspargase, Pegfilgrastim, Pemetrexed, Pentostatin, Pipobroman, Plicamycin, mithramycin, Porfimer sodium, Procarbazine, Rasburicase, Rituximab, Sargramostim, Streptozocin, Talc, Tamoxifen, Temozolomide, Teniposide, Testolactone, Thioguanine, Thiotepa, Topotecan, Toremifene, Tositumomab, Trastuzumab, Tretinoin, Uracil Mustard, Valrubicin, Vinblastine, Vincristine, Vinorelbine, Zoledronate, Sorafenib, Sutent, Thalomid, Revlimid, Vatalanib, ZD-6474, Neovastat, GSK-786024, AEE-788, AG-13736, AMG706, AZD-2171, BIBF-1120, CP-547,632, Midostaurin, SU-6668, CDP-791, PI-88, PCK-3145, Atiprimod, A6, Angiostatin, Cilengitide, Enodstatin, rPF4, Vitakin, Volociximab, 2-methoxyestradiol, AP-23573, Cancertinib, Actimid, Combretastatin A4 prodrug, Endo Tag 1, Enzastaurin, Ceflatonin, Silipide, INGN-241, OSI-461, Patupilone, Squalamine, Tacedinaline, UCN-01, UK-356202, Prednisolone, Methyl-prednisolone, Dexamethasone, and Epirubicin.

26. A method of inhibiting or reducing angiogenesis, comprising administering to a cell an effective amount of the AA targeting agent or a pharmaceutically acceptable salt thereof as claimed in claim 1, wherein the targeting agent binds angiogenesis related factor angiopoietin-2.

27. A method for treating a disease or symptom associated with an angiogenic disorder, comprising administering to the subject a therapeutically effective amount of the AA targeting agent or a pharmaceutically acceptable salt thereof as claimed in claim 1.

28. A method of inhibiting or reducing angiogenesis, comprising administering to a cell an effective amount of the AA targeting agent or pharmaceutically acceptable salt thereof as claimed in claim 19, wherein the targeting agent binds angiogenesis related factor angiopoietin-2.

29. A method for treating a disease or symptom associated with an angiogenic disorder, comprising administering to the subject a therapeutically effective amount of the AA targeting agent or a pharmaceutically acceptable salt thereof as claimed in claim 19.

Details for Patent 8,288,349

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 1978-01-10 ⤷  Try it Free 2026-11-10
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 1989-06-01 ⤷  Try it Free 2026-11-10
Amgen, Inc. EPOGEN/PROCRIT epoetin alfa Injection 103234 ⤷  Try it Free 2026-11-10
Amgen, Inc. PROCRIT epoetin alfa Injection 103234 ⤷  Try it Free 2026-11-10
Clinigen, Inc. PROLEUKIN aldesleukin For Injection 103293 1992-05-05 ⤷  Try it Free 2026-11-10
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 1991-02-20 ⤷  Try it Free 2026-11-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
AstraZeneca
Johnson and Johnson
Express Scripts
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.